Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

>Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients

 

PARIS, August 30, 2010 /PRNewswire-FirstCall/ --

- First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial. Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.

Effects on other clinical and MRI related outcomes further support the primary outcome. The safety profile was in line with previous clinical experience.

The TEMSO trial is the first study of a large phase III clinical development program to produce results on teriflunomide as monotherapy. Study findings from TEMSO will be presented during the platform presentation scheduled for October 15, 2010, starting at 9:15 a.m. CET at the 26th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. The TEMSO study results are embargoed until this oral presentation
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 The report “Adipic Acid ... Geography - Global Trends & Forecast to 2019” ... to market drivers, opportunities, and trends in different ... 27 figures spread through 217 slides and in-depth ... & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
(Date:10/25/2014)... New York, NY (PRWEB) October 23, 2014 ... today announced the winners for the 2014 BioProcess ... collaborations, business strategies, social corporate responsibility and technology ... better, more effective treatments to a global patient ... recognized by their peers during a very entertaining ...
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... are, important intracellular signals involved in the, ... growth, factors.The discovery of a phosphatidylinositol, ... of, the inositol ring uncovered a new ... signals., Phosphoinositide 3-kinase has been purified to, ...
... and CHT , Ceramic Hydroxyapatite ... Henry Lai, PhD, and Samuel G Franklin, PhD, Bio-Rad Laboratories, Inc., , ... , Introduction , ... using the conventional process composed of a protein A ...
... , Agencourt offers primer walking ... entire plasmid clones. Simply submit your template in either raw or , ... sequence. , Select from either single stranded coverage ... for publication quality or clone validation , purposes. ...
Cached Biology Technology:Purification of Phosphoinositide 3-Kinase With UNO Columns 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4Primer Walking 2
(Date:10/25/2014)... Oct.  22, 2014   MedNet Solutions , a ... management systems, is pleased to announce the 2014 ... – to be held in Bloomington, Minnesota ... to have record attendance and promises to be informative, ... The focus of the meeting is iMedNet™ ...
(Date:10/25/2014)... -- This report covers the specifics of microRNA (miRNA) ... pursuit of research due to its versatility and stability, ... RNA components. miRNA,s non-coding nature and ability to affect ... as a biomarker for a variety of diseases. This ... the advancement in therapeutic development. Furthermore there are a ...
(Date:10/25/2014)... , Oct. 22, 2014 A recent ... analysis of the current and future genetic testing market. ... and types are covered in this report. On account ... trends; drivers; and existing strengths and challenges; forecast for ... market is likely to grow at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... A test for the two strains of human papillomavirus responsible ... molecular assay uses a cervical scraping, like that for a ... 18, responsible for 70 percent of cervical cancers, says Dr. ... Gynecologic Cancer Prevention Center at the Medical College of Georgia. ...
... the world’s 162 species of grouper, a culinary favorite ... with extinction unless proper management or conservation measures are ... Conservation Union (IUCN) as under extinction threat, and the ... of 20 experts from 10 nations determined the extinction ...
... way primitive yeast make cholesterol, a team of ... counterpart controls cholesterol production and potentially drug metabolism. ... Hopkins University School of Medicine, Vanderbilt University, Indiana ... the February issue of Cell Metabolism. ...
Cached Biology News:New test for most virulent HPV strains under study 2New test for most virulent HPV strains under study 3Twenty of world's 162 grouper species threatened with extinction 2Primitive yeast yields secrets of human cholesterol and drug metabolism 2
For microscopy...
... cDNA Synthesis and Labeling Kit generates labeled ... First unmodified cDNA is made via a ... an Oligo(dT) primer. Unlike other methods, there ... the reverse transcription reaction. This unmodified cDNA ...
... high quality microarray scanner based on patented confocal ... spatial resolution. The DNAscope LM is unique ... scanner that is upgradeable to a total of ... Includes control module (computer), monitor, and ...
AC input: 50-60 Hz 115-120 V...
Biology Products: